Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Apr 2008
Randomized Controlled Trial Multicenter StudyClinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation.
Analyses of a trial in constipated patients indicated that lubiprostone may be an effective treatment for irritable bowel syndrome with constipation. ⋯ Lubiprostone significantly improved gastrointestinal symptoms of irritable bowel syndrome with constipation at all doses. Higher doses of lubiprostone, especially the 48 microg/day group, were associated with more gastrointestinal adverse events. From these data, the 16 microg/day dose demonstrated the optimal combination of efficacy and safety. These results warrant further study of lubiprostone for treatment of irritable bowel syndrome with constipation patients.
-
Aliment. Pharmacol. Ther. · Apr 2008
Randomized Controlled Trial Multicenter StudyClinical trial: a dose-response study of fospropofol disodium for moderate sedation during colonoscopy.
An effective agent is needed that provides rapid onset of sedation and quick recovery for patients undergoing colonoscopy. ⋯ The 6.5 mg/kg dose of fospropofol provides the ideal balance of efficacy and safety for patients undergoing colonoscopy and has been selected for phase 3 clinical development.